148 related articles for article (PubMed ID: 8680546)
1. Duration of anti-cholecystokinin (CCK) action on the rat exocrine pancreas of new CCK receptor antagonist FK480 administered orally.
Moriyoshi Y; Shiratori K; Iwabe C; Watanabe S; Takeuchi T
J Gastroenterol; 1996 Apr; 31(2):249-53. PubMed ID: 8680546
[TBL] [Abstract][Full Text] [Related]
2. Effect of a novel cholecystokinin receptor antagonist, FK480, administered intraduodenally, on pancreatic secretion in rats.
Moriyoshi Y; Shiratori K; Takeuchi T; Watanabe S
Pancreas; 1995 Apr; 10(3):295-300. PubMed ID: 7542771
[TBL] [Abstract][Full Text] [Related]
3. Effects of a new benzodiazepine derivative cholecystokinin receptor antagonist FK480 on pancreatic exocrine secretion in anesthetized rats.
Tachibana I; Otsuki M
Dig Dis Sci; 1994 Jun; 39(6):1321-8. PubMed ID: 8200267
[TBL] [Abstract][Full Text] [Related]
4. Different inhibitory effects of the newly developed CCK receptor antagonists FK480 and KSG-504 on pancreatic exocrine and endocrine secretion in the isolated perfused rat pancreas.
Kihara Y; Otsuki M
Pancreas; 1995 Mar; 10(2):109-17. PubMed ID: 7716133
[TBL] [Abstract][Full Text] [Related]
5. Augmentation of the inhibitory effect of FK480, a CCK-A receptor antagonist, on pancreatic exocrine secretion by achlorhydria.
Kuno M; Sogabe H; Ito H; Matsuo T; Satoh Y; Motoyama Y; Tanaka H
Pancreas; 1998 Jul; 17(1):57-64. PubMed ID: 9667521
[TBL] [Abstract][Full Text] [Related]
6. Characterization of a new cholecystokinin receptor antagonist FK480 in in vitro isolated rat pancreatic acini.
Akiyama T; Otsuki M
Pancreas; 1994 May; 9(3):324-31. PubMed ID: 8022754
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological profile of FK480, a novel cholecystokinin type-A receptor antagonist: comparison to loxiglumide.
Ito H; Sogabe H; Nakarai T; Sato Y; Tomoi M; Kadowaki M; Matsuo M; Tokoro K; Yoshida K
J Pharmacol Exp Ther; 1994 Feb; 268(2):571-5. PubMed ID: 7509389
[TBL] [Abstract][Full Text] [Related]
8. Effects of loxiglumide on pancreatic exocrine secretion stimulated by cholecystokinin-8 in conscious dogs.
Ninomiya K; Saito T; Wakatsuki K; Saeki M; Kato T; Kasai H; Kimura K; Fujii M
Arzneimittelforschung; 1998 Jan; 48(1):52-4. PubMed ID: 9522032
[TBL] [Abstract][Full Text] [Related]
9. Small intestinal and pancreatic microstructures are modified by an intraduodenal CCK-A receptor antagonist administration in neonatal calves.
Biernat M; Zabielski R; Sysa P; Sosak-Swiderska B; Le Huërou-Luron I; Guilloteau P
Regul Pept; 1999 Dec; 85(2-3):77-85. PubMed ID: 10651060
[TBL] [Abstract][Full Text] [Related]
10. Effects of loxiglumide on pancreatic exocrine secretion stimulated by meal in conscious dogs.
Ninomiya K; Saito T; Wakatsuki K; Saeki M; Kato T; Edano K; Kasai H; Kimura K; Fujii M
Arzneimittelforschung; 1998 Jan; 48(1):55-7. PubMed ID: 9522033
[TBL] [Abstract][Full Text] [Related]
11. [Inhibitory effect of CR 1409 (cholecystokinin antagonist) on pancreatic exocrine secretion in rats].
Shiratori K; Watanabe S; Shimizu K; Moriyoshi Y; Chang JH; Takeuchi T
Nihon Shokakibyo Gakkai Zasshi; 1989 Jan; 86(1):70-6. PubMed ID: 2471850
[TBL] [Abstract][Full Text] [Related]
12. Effect of FK480, a CCK-A receptor antagonist, on spontaneously developed chronic pancreatitis in WBN/Kob rats.
Ito H; Sogabe H; Kuno M; Satoh Y; Ogawa T; Konishi K; Yoshida K
Pancreas; 1998 Oct; 17(3):295-300. PubMed ID: 9788545
[TBL] [Abstract][Full Text] [Related]
13. Effect of cholecystokinin1 receptor antagonist loxiglumide (CR1505) on basal pancreatic exocrine secretion in conscious rats.
Ishizaki K; Kinbara S; Kawamura M; Kimura K; Shiratori K; Takeuchi T
Pancreas; 2003 Jan; 26(1):87-91. PubMed ID: 12499923
[TBL] [Abstract][Full Text] [Related]
14. Selective activation by photodynamic action of cholecystokinin receptor in the freshly isolated rat pancreatic acini.
An YP; Xiao R; Cui H; Cui ZJ
Br J Pharmacol; 2003 Jun; 139(4):872-80. PubMed ID: 12813011
[TBL] [Abstract][Full Text] [Related]
15. Effect of chronic oral administration of the CCK receptor antagonist loxiglumide on exocrine and endocrine pancreas in normal rats.
Imoto I; Yamamoto M; Jia DM; Otsuki M
Int J Pancreatol; 1997 Dec; 22(3):177-85. PubMed ID: 9444548
[TBL] [Abstract][Full Text] [Related]
16. Inhibitory effects of the cholecystokinin antagonist loxiglumide on pancreatic exocrine secretion and pancreatic growth in conscious rats.
Taguchi S; Green GM; Nakano I; Hatta Y
Int J Pancreatol; 1992 Apr; 11(2):67-73. PubMed ID: 1607730
[TBL] [Abstract][Full Text] [Related]
17. The effects of intrathecally administered FK480, a cholecystokinin-A receptor antagonist, and YM022, a cholecystokinin-B receptor antagonist, on the formalin test in the rat.
Yamamoto T; Nozaki-Taguchi N
Anesth Analg; 1996 Jul; 83(1):107-13. PubMed ID: 8659718
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological profile of T-0632, a novel potent and selective CCKA receptor antagonist, in vivo.
Taniguchi H; Yazaki N; Yomota E; Shikano T; Endo T; Nagasaki M
Eur J Pharmacol; 1996 Sep; 312(2):227-33. PubMed ID: 8894600
[TBL] [Abstract][Full Text] [Related]
19. Effect of CCK antagonists CR 1409 and CR 1505 on rat pancreatic exocrine secretion in vivo.
Shiratori K; Shimizu K; Watanabe S; Takeuchi T; Moriyoshi Y
Pancreas; 1989; 4(6):744-50. PubMed ID: 2813333
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the effects of two cholecystokinin-receptor antagonists, loxiglumide and L-364,718, on the pancreatic secretory response to intraduodenal tryptophan in dogs.
Niebergall-Roth E; Teyssen S; Wetzel D; Hartel M; Beglinger C; Riepl RL; Singer MV
Scand J Gastroenterol; 1996 Jul; 31(7):723-32. PubMed ID: 8819225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
